i4ne1nku

Property	Value
?:abstract	OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection METHODS: We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020 All COVID-19 patients with de novo neurologic manifestations were eligible RESULTS: We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61 3%) were male COVID-19 was severe or critical in 102 patients (45 2%) The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30 2%), acute ischaemic cerebrovascular syndrome (57/222, 25 7%), encephalitis (21/222, 9 5%) and Guillain-Barre syndrome (15/222, 6 8%) Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barre syndrome Brain imaging was performed in 192 patients (86 5%), including 157 magnetic resonance imaging (70 7%) Among patients with acute ischaemic cerebrovascular syndrome, 13 (22 8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28 1%) of 57 Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66 7%) of 21 Cerebrospinal fluid of 97 patients (43 7%) was analysed, with pleocytosis found in 18 patients (18 6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12 6%) CONCLUSIONS: Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020. All COVID-19 patients with de novo neurologic manifestations were eligible. RESULTS: We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France. Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61.3%) were male. COVID-19 was severe or critical in 102 patients (45.2%). The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30.2%), acute ischaemic cerebrovascular syndrome (57/222, 25.7%), encephalitis (21/222, 9.5%) and Guillain-Barré syndrome (15/222, 6.8%). Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barré syndrome. Brain imaging was performed in 192 patients (86.5%), including 157 magnetic resonance imaging (70.7%). Among patients with acute ischaemic cerebrovascular syndrome, 13 (22.8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28.1%) of 57. Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66.7%) of 21. Cerebrospinal fluid of 97 patients (43.7%) was analysed, with pleocytosis found in 18 patients (18.6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis. The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). CONCLUSIONS: Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/i4ne1nku_hasAnnotation_C0040053> <https://research.tib.eu/covid-19/entity/i4ne1nku_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/i4ne1nku_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Meppiel%2C_E.%3B_Peiffer-Smadja%2C_N.%3B_Maury%2C_A.%3B_Bekri%2C_I.%3B_Delorme%2C_C.%3B_Desestret%2C_V.%3B_Gorza%2C_L.%3B_Hautecloque-Raysz%2C_G.%3B_Landre%2C_S.%3B_Lannuzel%2C_A.%3B_Moulin%2C_S.%3B_Perrin%2C_P.%3B_Petitgas%2C_P.%3B_Sella%2C_F.%3B_Wang%2C_A.%3B_Tattevin%2C_P.%3B_de_Broucker%2C_T.%3B_contributors_to_the_Neuro%2C_Covid_registry> <https://research.tib.eu/covid-19/entity/Meppiel%2C_Elodie%3B_Peiffer-Smadja%2C_Nathan%3B_Maury%2C_Alexandra%3B_Bekri%2C_Imen%3B_Delorme%2C_C%C3%A9cile%3B_Desestret%2C_Virginie%3B_Gorza%2C_Lucas%3B_Hautecloque-Raysz%2C_Geoffroy%3B_Landre%2C_Sophie%3B_Lannuzel%2C_Annie%3B_Moulin%2C_Sol%C3%A8ne%3B_Perrin%2C_Peggy%3B_Petitgas%2C_Paul%3B_SellaI%2C_Fran%C3%A7ois%3B_Wang%2C_Adrien%3B_Tattevin%2C_Pierre%3B_de_Broucker%2C_Thomas>
?:journal	Clin._microbiol._infect Clinical_Microbiology_&_Infection
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/i4ne1nku_HAS_C1457887_ASSOCIATED_WITH_C0014038> <https://research.tib.eu/covid-19/entity/i4ne1nku_HAS_C1457887_ASSOCIATED_WITH_C0018378> <https://research.tib.eu/covid-19/entity/i4ne1nku_HAS_C1457887_ASSOCIATED_WITH_C0039082> <https://research.tib.eu/covid-19/entity/i4ne1nku_HAS_C1457887_ASSOCIATED_WITH_C0085584>
?:source	WHO
?:title	Neurologic manifestations associated with COVID-19: a multicentre registry
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#921867 #973978
?:year	2020

Property

Value

?:abstract

OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection METHODS: We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020 All COVID-19 patients with de novo neurologic manifestations were eligible RESULTS: We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61 3%) were male COVID-19 was severe or critical in 102 patients (45 2%) The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30 2%), acute ischaemic cerebrovascular syndrome (57/222, 25 7%), encephalitis (21/222, 9 5%) and Guillain-Barre syndrome (15/222, 6 8%) Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barre syndrome Brain imaging was performed in 192 patients (86 5%), including 157 magnetic resonance imaging (70 7%) Among patients with acute ischaemic cerebrovascular syndrome, 13 (22 8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28 1%) of 57 Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66 7%) of 21 Cerebrospinal fluid of 97 patients (43 7%) was analysed, with pleocytosis found in 18 patients (18 6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12 6%) CONCLUSIONS: Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes
OBJECTIVES: To provide an overview of the spectrum, characteristics and outcomes of neurologic manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We conducted a single-centre retrospective study during the French coronavirus disease 2019 (COVID-19) epidemic in March-April 2020. All COVID-19 patients with de novo neurologic manifestations were eligible. RESULTS: We included 222 COVID-19 patients with neurologic manifestations from 46 centres in France. Median (interquartile range, IQR) age was 65 (53-72) years and 136 patients (61.3%) were male. COVID-19 was severe or critical in 102 patients (45.2%). The most common neurologic diseases were COVID-19-associated encephalopathy (67/222, 30.2%), acute ischaemic cerebrovascular syndrome (57/222, 25.7%), encephalitis (21/222, 9.5%) and Guillain-Barré syndrome (15/222, 6.8%). Neurologic manifestations appeared after the first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19-associated encephalopathy, 7 (5-10) days in encephalitis, 12 (7-18) days in acute ischaemic cerebrovascular syndrome and 18 (15-28) days in Guillain-Barré syndrome. Brain imaging was performed in 192 patients (86.5%), including 157 magnetic resonance imaging (70.7%). Among patients with acute ischaemic cerebrovascular syndrome, 13 (22.8%) of 57 had multiterritory ischaemic strokes, with large vessel thrombosis in 16 (28.1%) of 57. Brain magnetic resonance imaging of encephalitis patients showed heterogeneous acute nonvascular lesions in 14 (66.7%) of 21. Cerebrospinal fluid of 97 patients (43.7%) was analysed, with pleocytosis found in 18 patients (18.6%) and a positive SARS-CoV-2 PCR result in two patients with encephalitis. The median (IQR) follow-up was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). CONCLUSIONS: Clinical spectrum and outcomes of neurologic manifestations associated with SARS-CoV-2 infection were broad and heterogeneous, suggesting different underlying pathogenic processes.

is ?:annotates of